MCC
SNDX icon

Money Concepts Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Money Concepts Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$5.09K – 2530
2022
Q4 		$5.09K Buy
+200
New +$4.67K ﹤0.01% 2338
2022
Q2 		– Sell
-200
Closed -$3K – 2467
2022
Q1 		$3K Buy
+200
New +$3.37K ﹤0.01% 2387

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Money Concepts Capital's SNDX Position: Q1 2023 in Review

Money Concepts Capital sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 200 shares — an estimated $5.09K sold.

Money Concepts Capital first reported a position in SNDX in Q1 2022 and held it in 2 quarters. The position peaked at $5.09K in Q4 2022. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

  • Money Concepts Capital reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 200 Syndax Pharmaceuticals shares in Q1 2023, an estimated $5.09K.
  • Money Concepts Capital first reported a position in Syndax Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Money Concepts Capital's Syndax Pharmaceuticals position peaked at $5.09K in Q4 2022.
  • 163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.